Search Result

Isoforms Recommended:	Akt2

Results for "

AKT2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (61) AMPK (4) Apoptosis (12) Autophagy (10) Bacterial (5) Bcl-2 Family (4) Casein Kinase (2) Caspase (5) DNA-PK (3) FKBP (2) GSK-3 (3) IKK (2) Influenza Virus (1) Isotope-Labeled Compounds (1) Ligands for E3 Ligase (1) MDM-2/p53 (3) Monoamine Oxidase (2) mTOR (3) NF-κB (4) Organoid (3) Parasite (3) PARP (3) PI3K (1) PKA (4) PKC (4) PROTAC Linkers (1) PROTACs (4) RANKL/RANK (2) Reactive Oxygen Species (ROS) (1) Reference Standards (12) Ribosomal S6 Kinase (RSK) (4) ROCK (4) Ser/Thr Protease (1) SGK (2) Small Interfering RNA (siRNA) (3) TGF-beta/Smad (2) TNF Receptor (2) VEGFR (1)
By Research Areas:	Cancer (62) Cardiovascular Disease (6) Infection (9) Inflammation/Immunology (9) Metabolic Disease (10) Neurological Disease (5)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Akt

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10358

MK-2206 dihydrochloride Maximum Cited Publications 462 Publications Verification MK-2206 (2HCl)	Bcl-2 Family Apoptosis mTOR Akt GSK-3	Cardiovascular Disease Inflammation/Immunology Cancer
MK-2206 dihydrochloride (MK-2206 2HCl) is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against **AKT1, AKT2 and AKT3, respectively. MK-2206 dihydrochloride inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 dihydrochloride induces G1-phase cell cycle arrest, apoptosis**, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 dihydrochloride causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 dihydrochloride can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia ^[2] .

HY-15431

Capivasertib 80+ Cited Publications AZD5363	Akt Autophagy	Cancer
Capivasertib (AZD5363) is an orally active and potent *pan-AKT* kinase inhibitor with IC₅₀ of 3, 7 and 7 nM for *Akt1,Akt2* and *Akt3*, respectively.

HY-N0004

Oridonin Maximum Cited Publications 26 Publications Verification NSC-250682; Isodonol	Akt Bacterial Ligands for E3 Ligase	Infection Inflammation/Immunology Cancer
Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of *AKT, with IC₅₀s of 8.4 and 8.9 μM for AKT1 and AKT2*; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.

HY-102080

SAFit2 5+ Cited Publications	FKBP	Cancer
SAFit2, a chemical probe, is a highly potent, highly selective FK506-binding protein 51 (FKBP51) inhibitor with a K_i of 6 nM and also enhances *AKT2-AS160* binding .

HY-108232

MK-2206 Maximum Cited Publications 462 Publications Verification	Bcl-2 Family Apoptosis mTOR Akt GSK-3	Metabolic Disease Inflammation/Immunology Cancer
MK-2206 is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against **AKT1, AKT2 and AKT3, respectively. MK-2206 inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 induces G1-phase cell cycle arrest, apoptosis**, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia ^[2] .

HY-10355

AKT inhibitor VIII 55+ Cited Publications AKTi-1/2	Akt Apoptosis	Metabolic Disease Cancer
AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit *Akt1, Akt2, and Akt3* activity with IC₅₀s of 58 nM, 210 nM, and 2119 nM, respectively.

HY-15965

Uprosertib 15+ Cited Publications GSK2141795	Akt	Cancer
Uprosertib (GSK2141795) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-15727

Afuresertib 15+ Cited Publications GSK2110183; LAE002	Akt PKC ROCK	Cancer
Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively ^[2].

HY-100018

BAY1125976 3 Publications Verification	Akt	Cancer
BAY1125976, a chemical probe, is a selective allosteric *Akt1/Akt2* inhibitor; inhibits Akt1 and Akt2 activity with IC₅₀ values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

HY-19719

Miransertib 15+ Cited Publications ARQ-092	Akt Parasite	Infection Cancer
Miransertib (ARQ-092) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib is effective against Leishmania* ^[2].

HY-133120

INY-03-041 1 Publications Verification	PROTACs Akt	Cancer
INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive *AKT* inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits *AKT1, AKT2* and *AKT3* with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively .

HY-10249

GSK-690693 40+ Cited Publications	Akt AMPK Autophagy	Cancer
GSK-690693 is an ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 2 nM, 13 nM, 9 nM for *Akt1, Akt2* and *Akt3, respectively. GSK-690693 is also an AMPK* inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation ^[2] .

HY-10425

Rizavasertib 10+ Cited Publications A-443654	Akt	Cancer
A-443654 is a *pan-Akt* inhibitor and has equal potency against *Akt1, Akt2, or Akt3* within cells (K_i=160 pM) .

HY-13260

CCT128930 5+ Cited Publications	Akt Autophagy Apoptosis	Cancer
CCT128930 is a ATP-competitive and selective inhibitor of *AKT* (IC₅₀=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). Antitumor activity.

HY-N0559

Kirenol 1 Publications Verification	Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target *CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53* and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the *CK2/AKT* and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis ^[2] .

HY-151504

Engasertib 2 Publications Verification ALM301	Akt	Cancer
Engasertib is an orally active highly specific *AKT* inhibitor with IC₅₀ values of 0.13 µM, 0.09 µM and 2.75 µM for AKT1, AKT2 and AKT3, respectively. Engasertib inhibits AKT phosphorylation and modulates downstream signalling in vitro. Engasertib can inhibit cancer cell proliferation and tumor growth .

HY-N0026

2'-Acetylacteoside 1 Publications Verification 2'-AA	Monoamine Oxidase RANKL/RANK TNF Receptor NF-κB IKK	Cardiovascular Disease Neurological Disease Metabolic Disease
2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC₅₀ = 17.71 μM, K_i = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease ^[2] .

HY-19719A

Miransertib hydrochloride 15+ Cited Publications ARQ-092 hydrochloride	Akt Parasite	Infection Cancer
Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib hydrochloride is effective against Leishmania* ^[2].

HY-15186A

Ipatasertib dihydrochloride 55+ Cited Publications GDC-0068 dihydrochloride; RG-7440 dihydrochloride	Organoid Akt	Cancer
Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 5, 18 and 8 nM for *Akt1, Akt2* and *Akt3*, respectively.

HY-15727A

Afuresertib hydrochloride 15+ Cited Publications GSK2110183 hydrochloride; LAE002 hydrochloride	Akt PKC ROCK	Cancer
Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively ^[2].

HY-12059

AT7867 5 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-132302

Hu7691	Akt PKA PKC ROCK Ribosomal S6 Kinase (RSK) SGK	Cancer
Hu7691 is an orally active, selective *Akt* inhibitor with IC₅₀s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice .

HY-50862

Akt1/Akt2-IN-1 2 Publications Verification	Akt	Cancer
Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of *Akt1* (IC₅₀=3.5 nM) and *Akt2* (IC₅₀=42 nM), with potent and balanced activity .

HY-B0960

Sulfabenzamide 1 Publications Verification N-Sulfanilylbenzamide	Bacterial Autophagy MDM-2/p53 Caspase PARP DNA-PK Akt	Infection Cancer
Sulfabenzamide (N-Sulfanilylbenzamide) is a sulfonamide antibacterial agent. Sulfabenzamide exhibit antibacterial activity against Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 8739). Sulfabenzamide can promote autophagic cell autophagy in breast cancer cells through p53/ DRAM pathway. Sulfabenzamide increases caspase-3 activity, deactivates PARP1 and DNA-PK, downregulates *AKT1* and *AKT2*. Sulfabenzamide can be used for the researches of breast cancer and bacterial infections ^[2].

HY-137458

Vevorisertib 1 Publications Verification ARQ 751	Akt Ser/Thr Protease	Cancer
Vevorisertib (ARQ 751) is an orally active, potent and selective *pan-AKT* serine/threonine kinase inhibitor against *AKT1* (IC₅₀=0.55 nM), *AKT2* (IC₅₀=0.81 nM), and *AKT3* (IC₅₀=1.31 nM). Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations ^[2] .

HY-137458A

Vevorisertib trihydrochloride 1 Publications Verification ARQ 751 trihydrochloride	Akt	Cancer
Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC₅₀ values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer .

HY-19982

AKT-IN-6 2 Publications Verification	Akt	Cancer
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC₅₀s < 500nM, respectively. (patent WO2013056015A1).

HY-16666

3CAI 4 Publications Verification	Akt	Cancer
3CAI is a potent and specific *AKT1* and *AKT2* inhibitor.

HY-129119

Akt1/Akt2-IN-2	Akt Caspase	Cancer
Akt1/Akt2-IN-2 (compound 7) is an allosteric dual *Akt1* and *Akt2* inhibitor (IC₅₀=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells .

HY-145282

MS170 1 Publications Verification	PROTACs Akt	Cancer
MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total *AKT* (T-AKT) with the DC₅₀ value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with K_ds of 1.3 nM, 77 nM, and 6.5 nM, respectively .

HY-133120A

INY-03-041 trihydrochloride 1 Publications Verification	PROTACs Akt	Cancer
INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive *AKT* inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003). INY-03-041 trihydrochloride inhibits *AKT1, AKT2* and *AKT3* with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively .

HY-N2902

Artocarpin	Reactive Oxygen Species (ROS)	Cancer
Artocarpin is an orally active apoptosis inducer. Artocarpin targets NF-κB, *Erk1/2, p38 MAPK, AktS473, p53, Akt* 1 kinase and Akt 2 kinase. Artocarpin induces reactive oxygen species (ROS) production, mediates p53-dependent and p53-independent apoptotic signaling pathways, induces G1-phase cell cycle arrest, and triggers autophagic cell death. Artocarpin exerts cytotoxic and bactericidal effects on cancer cells, reduces bacterial load, and exhibits anti-inflammatory, analgesic and anti-angiogenic activities ^[2] .

HY-12059A

AT7867 dihydrochloride 5 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-B1080A

Tilorone 2 Publications Verification	Influenza Virus Akt	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels ^[2] .

HY-126257

AKT-IN-3	Akt Apoptosis	Cancer
AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking *Akt* inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells .

HY-145281

MS98	PROTACs Akt	Cancer
MS98 is a potent and selective PROTAC AKT degrader. MS98 depletes cellular total *AKT* (T-AKT) with the DC₅₀ value of 78 nM. MS98 binds to AKT1, AKT2, and AKT3 with K_ds of 4 nM, 140 nM, and 8.1 nM, respectively .

HY-RS00546

AKT2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Akt	Others
AKT2 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AKT2 Human Pre-designed siRNA Set A AKT2 Human Pre-designed siRNA Set A

HY-RS00547

Akt2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Akt	Others
Akt2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akt2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt2 Mouse Pre-designed siRNA Set A Akt2 Mouse Pre-designed siRNA Set A

HY-RS00548

Akt2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Akt	Others
Akt2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Akt2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt2 Rat Pre-designed siRNA Set A Akt2 Rat Pre-designed siRNA Set A

HY-15431R

Capivasertib (Standard) AZD5363 (Standard)	Akt Autophagy Reference Standards	Cancer
Capivasertib (Standard) is the analytical standard of Capivasertib. This product is intended for research and analytical applications. Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.

HY-10357

MK-2206 free base	Akt mTOR Apoptosis GSK-3 Bcl-2 Family	Metabolic Disease Inflammation/Immunology Cancer
MK-2206 free base is an orally active pan-AKT inhibitor, with IC₅₀ values of 8 nM, 12 nM and 65 nM against **AKT1, AKT2 and AKT3, respectively. MK-2206 free base inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 free base induces G1-phase cell cycle arrest, apoptosis**, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 free base causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 free base can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia ^[2] .

HY-B0960S

Sulfabenzamide-d4 N-Sulfanilylbenzamide-d₄	Bacterial Autophagy Isotope-Labeled Compounds MDM-2/p53 Caspase PARP DNA-PK Akt	Infection Cancer
Sulfabenzamide (N-Sulfanilylbenzamide)-d₄ is the deuterium labeled Sulfabenzamide (HY-B0960). Sulfabenzamide is a sulfonamide antibacterial agent. Sulfabenzamide exhibit antibacterial activity against Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 8739). Sulfabenzamide can promote autophagic cell autophagy in breast cancer cells through p53/ DRAM pathway. Sulfabenzamide increases caspase-3 activity, deactivates PARP1 and DNA-PK, downregulates *AKT1* and *AKT2*. Sulfabenzamide can be used for the researches of breast cancer and bacterial infections ^[2].

HY-130985

9-Decyn-1-ol	PROTAC Linkers	Cancer
9-Decyn-1-ol is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs. 9-Decyn-1-ol can be used to conjugate GDC-0068 with Lenalidomide to generate INY-03-041. INY-03-041 is a potent, highly selective and PROTAC-based pan-Akt degrader. INY-03-041 inhibits Akt1, Akt2 and Akt3 with IC₅₀s of 2.0 nM, 6.8 nM and 3.5 nM, respectively . 9-Decyn-1-ol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-153640

AKT-IN-14	Akt	Cancer
AKT-IN-14 (Example 2) is a potent AKTinhibitor with the IC₅₀ values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 can be used in cancer research .

HY-15965A

Uprosertib hydrochloride GSK2141795 hydrochloride	Akt	Cancer
Uprosertib hydrochloride (GSK2141795 hydrochloride) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-132302A

Hu7691 free base	Akt PKA PKC ROCK Ribosomal S6 Kinase (RSK) SGK	Cancer
Hu7691 free base is an orally active, selective *Akt* inhibitor with IC₅₀s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice .

HY-N0004R

Oridonin (Standard) NSC-250682 (Standard); Isodonol (Standard)	Reference Standards Akt Bacterial	Infection Inflammation/Immunology Cancer
Oridonin (Standard) is the analytical standard of Oridonin. This product is intended for research and analytical applications. Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.

HY-E70791

*Biotin-AKT2* Recombinant Human Active Protein Kinase**	Akt	Cancer
AKT is the oncogenic protein kinase that regulates essential cellular functions such as migration, proliferation, differentiation, apoptosis, and metabolism. Mammalian cells are characterized by the expression of three different Akt isoforms, Akt1, Akt2, and Akt3. Biotin-AKT2 Recombinant Human Active Protein Kinase is obtained by expressing AKT2 proteins and is biotinylated .

HY-E70786

AKT1 E17K Recombinant Human Active Protein Kinase	Akt	Cancer
AKT is the oncogenic protein kinase that regulates essential cellular functions such as migration, proliferation, differentiation, apoptosis, and metabolism. Mammalian cells are characterized by the expression of three different Akt isoforms, Akt1, Akt2, and Akt3. AKT1 E17K is a mutant of AKT1. AKT1 E17K Recombinant Human Active Protein Kinase is obtained by expressing AKT1 E17K proteins .

HY-B0960R

Sulfabenzamide (Standard) N-Sulfanilylbenzamide (Standard)	Reference Standards Bacterial Autophagy MDM-2/p53 Caspase PARP DNA-PK Akt	Infection Cancer
Sulfabenzamide (N-Sulfanilylbenzamide) (Standard) is the analytical standard of Sulfabenzamide (HY-B0960). This product is intended for research and analytical applications. Sulfabenzamide is a sulfonamide antibacterial agent. Sulfabenzamide exhibit antibacterial activity against Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 8739). Sulfabenzamide can promote autophagic cell autophagy in breast cancer cells through p53/ DRAM pathway. Sulfabenzamide increases caspase-3 activity, deactivates PARP1 and DNA-PK, downregulates *AKT1* and *AKT2*. Sulfabenzamide can be used for the researches of breast cancer and bacterial infections ^[2].

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library

4,096 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 4,096 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0004

Oridonin Maximum Cited Publications 26 Publications Verification NSC-250682; Isodonol	Infection Structural Classification Classification of Application Fields Terpenoids Labiatae Diterpenoids Plants Inflammation/Immunology Disease Research Fields Butea monosperma Kuntze	Akt Bacterial Ligands for E3 Ligase
Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of *AKT, with IC₅₀s of 8.4 and 8.9 μM for AKT1 and AKT2*; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.

HY-N0559

Kirenol 1 Publications Verification	Structural Classification Terpenoids Bituminaria morisiana (Pignatti & Metlesics) Greuter Diterpenoids Plants Compositae Source Classification	Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target *CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53* and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the *CK2/AKT* and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis ^[2] .

HY-N0026

2'-Acetylacteoside 1 Publications Verification 2'-AA	Structural Classification Classification of Application Fields Simple Phenylpropanols Other Diseases Scrophulariaceae Phenylpropanoids Plants Disease Research Fields Brandisia hancei Hook. f. Source Classification	Monoamine Oxidase RANKL/RANK TNF Receptor NF-κB IKK
2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC₅₀ = 17.71 μM, K_i = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease ^[2] .

HY-N2902

Artocarpin	Structural Classification Flavonols Flavonoids Plants Moraceae Source Classification	Reactive Oxygen Species (ROS)
Artocarpin is an orally active apoptosis inducer. Artocarpin targets NF-κB, *Erk1/2, p38 MAPK, AktS473, p53, Akt* 1 kinase and Akt 2 kinase. Artocarpin induces reactive oxygen species (ROS) production, mediates p53-dependent and p53-independent apoptotic signaling pathways, induces G1-phase cell cycle arrest, and triggers autophagic cell death. Artocarpin exerts cytotoxic and bactericidal effects on cancer cells, reduces bacterial load, and exhibits anti-inflammatory, analgesic and anti-angiogenic activities ^[2] .

HY-N0004R

Oridonin (Standard) NSC-250682 (Standard); Isodonol (Standard)	Structural Classification Terpenoids Labiatae Diterpenoids Plants Butea monosperma Kuntze	Reference Standards Akt Bacterial
Oridonin (Standard) is the analytical standard of Oridonin. This product is intended for research and analytical applications. Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.

HY-N0026R

2'-Acetylacteoside (Standard) 2'-AA (Standard)	Structural Classification Simple Phenylpropanols Scrophulariaceae Phenylpropanoids Plants Brandisia hancei Hook. f. Source Classification	Reference Standards Monoamine Oxidase RANKL/RANK TNF Receptor NF-κB IKK
2'-Acetylacteoside (Standard) is the analytical standard of 2'-Acetylacteoside (2'-AA) (HY-N0026). This product is intended for research and analytical applications. 2'-Acetylacteoside is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC₅₀ = 17.71 μM, K_i = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease ^[2] .

HY-N0559R

Kirenol (Standard)	Structural Classification Terpenoids Bituminaria morisiana (Pignatti & Metlesics) Greuter Diterpenoids Plants Compositae Source Classification	Reference Standards Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad
Kirenol (Standard) is the analytical standard of Kirenol (HY-N0559). This product is intended for research and analytical applications. Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis.

Recombinant Proteins Recommended:

AKT Serine/Threonine Kinase 2 (AKT2)

Species:	Human (3) Mouse (1)
Tag:	His (3) Myc (1) GST (3)
Source:	sf9 insect cells (1) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P74420

	AKT2 Protein, Human (sf9, His-GST) 1 Publications Verification RAC-beta serine/threonine-protein kinase; PKB beta; AKT2	Human	Sf9 insect cells
	The AKT2 protein is a serine/threonine protein kinase in the AKT family that is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage. AKT2 Protein, Human (sf9, His-GST) is the recombinant human-derived AKT2 protein, expressed by Sf9 insect cells , with C-His, N-GST labeled tag.

HY-P702632

	AKT2 Protein, Human (Active, sf9, GST) AKT2; v-AKT murine thymoma viral oncogene homolog 2; PKBB; PRKBB; PKBBETA; RAC-BETA; AKT2 kinase; rac protein kinase beta; Murine thymoma viral (v-AKT) homolog-2; EC 2.7.11.1; RAC-beta serine/threonine-protein kinase; RAC-PK-beta; Protein kinase AKT-2; Protein kinase B, beta; PKB beta	Human	Sf9 insect cells
	The AKT2 protein is a serine/threonine protein kinase in the AKT family that is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage. AKT2 Protein, Human (Active, sf9, GST) is the recombinant human-derived AKT2, expressed by Sf9 insect cells, with GST labeled tag. The total length of AKT2 Protein, Human (Active, sf9, GST) is 480 a.a..

HY-P705728

	AKT2 Protein, Human (Active, E17K, sf9, His-GST) AKT2; v-AKT murine thymoma viral oncogene homolog 2; PKBB; PRKBB; PKBBETA; RAC-BETA; AKT2 kinase; rac protein kinase beta; Murine thymoma viral (v-AKT) homolog-2; EC 2.7.11.1; RAC-beta serine/threonine-protein kinase; RAC-PK-beta; Protein kinase AKT-2; Protein kinase B, beta; PKB beta	Human	sf9 insect cells

HY-P702854

	AKT2 Protein, Mouse (His, Myc) Protein kinase AKT-2; Protein kinase B beta; PKB beta; RAC-PK-beta	Mouse	E. coli
	AKT2 Protein, Mouse (His, Myc) is the recombinant mouse-derived AKT2, expressed by E. coli, with N-10*His, C-Myc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0960S

Sulfabenzamide-d4

Sulfabenzamide (N-Sulfanilylbenzamide)-d₄ is the deuterium labeled Sulfabenzamide (HY-B0960). Sulfabenzamide is a sulfonamide antibacterial agent. Sulfabenzamide exhibit antibacterial activity against Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 8739). Sulfabenzamide can promote autophagic cell autophagy in breast cancer cells through p53/ DRAM pathway. Sulfabenzamide increases caspase-3 activity, deactivates PARP1 and DNA-PK, downregulates AKT1 and AKT2. Sulfabenzamide can be used for the researches of breast cancer and bacterial infections ^[2].

Host:	Mouse (2) Rabbit (5)
Reactivity:	Human (7) Mouse (5) Rat (5) Monkey (2) Hamster (2)
Application:	IHC-P (6) ICC/IF (5) IP (3) IHC-F (2) WB (7) FC (2) ELISA (2)
Isotype:	IgG (5) IgG2b (2)
Conjugation:	Non-conjugated (7)
Clonality:	Monoclonal (2) Monoclonal Antibody (1) Recombinant (2)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84255

	AKT2 Antibody (YA3952) PKBB; PRKBB; PKBBETA; RAC-BETA	WB, IHC-P, ICC/IF, ELISA	Human, Rat, Monkey
	AKT2 Antibody (YA3952) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to AKT2.

HY-P84255A

	AKT2 Antibody (YA3952)(PBS only) PKBB; PRKBB; PKBBETA; RAC-BETA	WB, IHC-P, ICC/IF, ELISA	Human, Rat, Monkey
	AKT2 Antibody (YA3952) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to AKT2.

HY-P80535

	AKT1+AKT2+AKT3 Antibody (YA635) 5 Publications Verification AKT1,AKT2,AKT3	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Hamster
	AKT1+AKT2+AKT3 Antibody (YA635) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1+AKT2+AKT3.

HY-P80535A

	AKT1+AKT2+AKT3 Antibody (YA635)(PBS only) AKT1,AKT2,AKT3	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Hamster
	AKT1+AKT2+AKT3 Antibody (YA635) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1+AKT2+AKT3.

HY-P80009

	AKT1/2/3 Antibody (YA633) 1 Publications Verification	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	AKT1/2/3 Antibody (YA633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to AKT1/2/3.

HY-P810595

	*Phospho-AKT2* (Ser474) Antibody** PKBB; PRKBB; PKBBETA; RAC-BETA	WB, IHC-P	Human, Mouse
	Phospho-AKT2 (Ser474) Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Phospho-AKT2 (Ser474).

HY-P810596

	*Phospho-AKT2* (Ser474) Antibody (YA9859)** PKBB; PRKBB; PKBBETA; RAC-BETA	WB, FC	Human, Mouse, Rat
	Phospho-AKT2 (Ser474) Antibody (YA9859) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-AKT2 (Ser474).